» Articles » PMID: 28780023

Shared ACVR1 Mutations in FOP and DIPG: Opportunities and Challenges in Extending Biological and Clinical Implications Across Rare Diseases

Overview
Journal Bone
Date 2017 Aug 7
PMID 28780023
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Gain-of-function mutations in the Type I Bone Morphogenic Protein (BMP) receptor ACVR1 have been identified in two diseases: Fibrodysplasia Ossificans Progressiva (FOP), a rare autosomal dominant disorder characterized by genetically driven heterotopic ossification, and in 20-25% of Diffuse Intrinsic Pontine Gliomas (DIPGs), a pediatric brain tumor with no effective therapies and dismal median survival. While the ACVR1 mutation is causal for FOP, its role in DIPG tumor biology remains under active investigation. Here, we discuss cross-fertilization between the FOP and DIPG fields, focusing on the biological mechanisms and principles gleaned from FOP that can be applied to DIPG biology. We highlight our current knowledge of ACVR1 in both diseases, and then describe the growing opportunities and barriers to effectively investigate ACVR1 in DIPG. Importantly, learning from other seemingly unrelated diseases harboring similar mutations may uncover novel mechanisms or processes for future investigation.

Citing Articles

Molecular Developmental Biology of Fibrodysplasia Ossificans Progressiva: Measuring the Giant by Its Toe.

Towler O, Shore E, Kaplan F Biomolecules. 2024; 14(8).

PMID: 39199396 PMC: 11353020. DOI: 10.3390/biom14081009.


Context-dependent TGFβ family signalling in cell fate regulation.

Richardson L, Wilcockson S, Guglielmi L, Hill C Nat Rev Mol Cell Biol. 2023; 24(12):876-894.

PMID: 37596501 DOI: 10.1038/s41580-023-00638-3.


Molecular Characterization and Treatment Approaches for Pediatric -Altered Diffuse Midline Glioma: Integrated Systematic Review of Individual Clinical Trial Participant Data.

Damodharan S, Abbott A, Kellar K, Zhao Q, Dey M Cancers (Basel). 2023; 15(13).

PMID: 37444588 PMC: 10340772. DOI: 10.3390/cancers15133478.


Bone morphogenetic protein signaling is a possible therapeutic target in gynecologic cancer.

Fukuda T, Suzuki E, Fukuda R Cancer Sci. 2022; 114(3):722-729.

PMID: 36468782 PMC: 9986083. DOI: 10.1111/cas.15682.


Targeted therapy for pediatric diffuse intrinsic pontine glioma: a single-center experience.

Del Baldo G, Carai A, Abbas R, Cacchione A, Vinci M, Di Ruscio V Ther Adv Med Oncol. 2022; 14:17588359221113693.

PMID: 36090803 PMC: 9459464. DOI: 10.1177/17588359221113693.


References
1.
Gregson C, Hollingworth P, Williams M, Petrie K, Bullock A, Brown M . A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date. Bone. 2010; 48(3):654-8. PMC: 3160462. DOI: 10.1016/j.bone.2010.10.164. View

2.
Waite K, Eng C . From developmental disorder to heritable cancer: it's all in the BMP/TGF-beta family. Nat Rev Genet. 2003; 4(10):763-73. DOI: 10.1038/nrg1178. View

3.
Chan K, Fang D, Gan H, Hashizume R, Yu C, Schroeder M . The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 2013; 27(9):985-90. PMC: 3656328. DOI: 10.1101/gad.217778.113. View

4.
Monje M, Mitra S, Freret M, Raveh T, Kim J, Masek M . Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci U S A. 2011; 108(11):4453-8. PMC: 3060250. DOI: 10.1073/pnas.1101657108. View

5.
Taylor K, Mackay A, Truffaux N, Butterfield Y, Morozova O, Philippe C . Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet. 2014; 46(5):457-461. PMC: 4018681. DOI: 10.1038/ng.2925. View